1093063-92-3

Basic information

• Product Name: 1-benzyl-4-(4-bromo-phenyl)-4-methyl-piperidine
• Synonyms: 1-benzyl-4-(4-bromo-phenyl)-4-methyl-piperidine
• CAS NO: 1093063-92-3
• Molecular Weight: 344.294
• Mol File: 1093063-92-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-benzyl-4-(4-bromo-phenyl)-4-methyl-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-(4-bromo-phenyl)-4-methyl-piperidine(1093063-92-3)
• EPA Substance Registry System: 1-benzyl-4-(4-bromo-phenyl)-4-methyl-piperidine(1093063-92-3)

Safety Data

• Hazardous Substances Data: 1093063-92-3(Hazardous Substances Data)

Upstream product

• 108-86-1 bromobenzene 
• 3970-66-9 1-benzyl-4-methyl-piperidin-4-ol 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 83949-37-5 4-methyl-4-phenylpiperidine hydrochloride 
• 1093064-92-6 C₁₈H₂₀ClN₃O 
• 1093063-93-4 C₂₃H₂₅N₃ 
• 1093063-94-5 C₁₆H₁₉N₃ 

Relevant articles and documents

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER

Disclosed are the ERK inhibitors of formula 1.0: (Chemical formula should be inserted here as it appears on abstract in paper form) and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.